US › Healthcare

Humacyte Inc (HUMA)

US · Healthcare · Biotechnology

$0.71+3.32%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$495,000
Revenue YoY
-4.3%
Net profit
$-17.6M
Profit YoY
-145.0%
EPS
$-0.09
EPS estimate
$-0.11
Net margin
-3,559.4%

EPS came in at -0.09 against a street estimate of -0.11 — a beat of 18.2%.

Key statistics

Market cap
$176.2M
Forward P/E
35.8
P/B
15.18
Book value
$0.05
EPS (TTM)
$-0.63
52-week high
$2.76
52-week low
$0.55
50-day MA
$0.90
200-day MA
$1.05
Beta
2.52

Analyst view

Analysts rate Humacyte Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $2.05.

Shareholding

Insiders
7.51%
Institutions
22.29%

Largest institutional holders

FundStake
BlackRock Inc4.57%
Vanguard Capital Management, LLC2.65%
Antipodes Partners Limited2.12%
Great Point Partners LLC1.39%
Geode Capital Management, LLC1.36%
State Street Corp1.13%
UBS Group AG1.03%
Woodline Partners LP0.74%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Humacyte Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.